| A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ) (NCT01227551) | Viralytics | 2011-12-29 |
| Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma (NCT01321437) | University of California, Irvine | 2011-12-01 |
| Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma (NCT01435369) | Medivation, Inc. | 2011-11-01 |
| Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E (NCT01586195) | Genentech, Inc. | 2011-10-31 |
| Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors (NCT01455259) | Uppsala University | 2011-09-01 |
| A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases (NCT01378975) | Hoffmann-La Roche | 2011-07-01 |
| A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy (NCT02223884) | Yonsei University | 2011-07-01 |
| A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab (NCT01307267) | Pfizer | 2011-06-21 |
| Lapatinib in Stage IV Melanoma With ERBB4 Mutations (NCT01264081) | National Cancer Institute (NCI) | 2011-05-20 |
| Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma (NCT01557114) | Gustave Roussy, Cancer Campus, Grand Paris | 2011-03-01 |
| A Study of Vemurafenib in Participants With Metastatic Melanoma (NCT01307397) | Hoffmann-La Roche | 2011-03-01 |
| A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma (NCT01271803) | Hoffmann-La Roche | 2011-02-17 |
| A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma (NCT01264380) | Hoffmann-La Roche | 2011-01-01 |
| A Study of RO5185426 in Patients With Metastatic Melanoma (NCT01248936) | Hoffmann-La Roche | 2010-12-01 |
| Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma (NCT01211262) | Immunocore Ltd | 2010-09-28 |
| A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma (NCT01164891) | Hoffmann-La Roche | 2010-07-01 |
| Early Diagnosis of Malignant Transformation of Pigmentary Skin Lesions (NCT01167998) | Hadassah Medical Organization | 2010-07-01 |
| An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma (NCT01137006) | Eli Lilly and Company | 2010-06-01 |
| A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma (NCT01107418) | Hoffmann-La Roche | 2010-05-01 |
| Study of a DNA Immunotherapy to Treat Melanoma (NCT01138410) | Scancell Ltd | 2010-05-01 |
| Intratumoral Application of L19IL2 in Patients With Malignant Melanoma (NCT01253096) | Philogen S.p.A. | 2010-04-01 |
| SciBase International Melanoma Pivotal Study (NCT01077050) | SciBase AB | 2010-04-01 |
| IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma (NCT01288963) | Beth Israel Deaconess Medical Center | 2010-02-01 |
| A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) (NCT01006980) | Hoffmann-La Roche | 2010-01-01 |
| Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (NCT01024231) | Bristol-Myers Squibb | 2009-12-14 |
| Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma (NCT00963664) | NeoPlas Innovation | 2009-12-01 |
| A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma (NCT01001299) | Hoffmann-La Roche | 2009-11-30 |
| SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma (NCT00991250) | SentoClone AB | 2009-10-01 |
| A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma (NCT00949702) | Hoffmann-La Roche | 2009-09-30 |
| Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma (NCT00978913) | Inge Marie Svane | 2009-09-01 |
| Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions (NCT01017185) | Takara Bio Inc. | 2009-08-01 |
| A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma (NCT00864253) | Celgene | 2009-04-23 |
| Quality of Life and Psychological Well-being in Patients With Malignant Melanoma (NCT00963261) | University Hospital Freiburg | 2009-04-01 |
| Comparison of Video-Based Versus Written Patient Education on Melanoma (NCT00826995) | University of California, Davis | 2009-01-01 |
| Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors (NCT00855452) | Hadassah Medical Organization | 2009-01-01 |
| The Identification of Novel Prognostic Markers in Melanoma (NCT01002560) | Royal Marsden NHS Foundation Trust | 2008-12-01 |
| Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi (NCT00862914) | Ruhr University of Bochum | 2008-07-01 |
| Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies (NCT00710515) | AstraZeneca | 2008-07-01 |
| Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma (NCT00715793) | Hussein Tawbi | 2008-06-01 |
| Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma (NCT00539591) | St. Jude Children's Research Hospital | 2008-05-09 |
| Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients (NCT00651703) | Cytos Biotechnology AG | 2008-04-01 |
| Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer (NCT00601861) | Novo Nordisk A/S | 2008-02-13 |
| In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer (NCT00631072) | Beth Israel Deaconess Medical Center | 2008-02-01 |
| Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma (NCT00924001) | National Cancer Institute (NCI) | 2007-08-01 |
| Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma (NCT00513604) | National Cancer Institute (NCI) | 2007-06-01 |
| A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma (NCT00483301) | Mt. Sinai Medical Center, Miami | 2007-05-01 |
| Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens (NCT00204516) | University Hospital Tuebingen | 2007-04-01 |
| Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma (NCT00498836) | Clavis Pharma | 2007-03-01 |
| A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma (NCT01069627) | Hoffmann-La Roche | 2006-12-01 |
| Safety Study of PLX4032 in Patients With Solid Tumors (NCT00405587) | Plexxikon | 2006-11-01 |
| Sentinel Node With Ultrasound Contrast in Melanoma (NCT00370136) | Rigshospitalet, Denmark | 2006-08-01 |
| A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies (NCT00441337) | Bristol-Myers Squibb | 2006-08-01 |
| A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma (NCT01164007) | Hoffmann-La Roche | 2006-06-30 |
| Phase II Trial of Ontak With Metastatic Melanoma (NCT00299689) | James Graham Brown Cancer Center | 2006-03-01 |
| Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma (NCT00616564) | Mt. Sinai Medical Center, Miami | 2006-02-01 |
| A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide (NCT00135408) | Bristol-Myers Squibb | 2005-12-01 |
| FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma (NCT00104884) | ECOG-ACRIN Cancer Research Group | 2005-10-04 |
| Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28 (NCT00204594) | University Hospital Tuebingen | 2005-10-01 |
| Clinical Study of Previously Untreated Patients With Malignant Melanoma (NCT00232726) | Clavis Pharma | 2005-09-01 |
| NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) (NCT00142454) | Ludwig Institute for Cancer Research | 2005-08-24 |
| Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma (NCT00327600) | AmpliMed Corporation | 2005-07-01 |
| IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma (NCT00294476) | GammaCan | 2005-07-01 |
| Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma (NCT00116363) | Introgen Therapeutics | 2005-03-01 |
| Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma (NCT00358319) | H. Lee Moffitt Cancer Center and Research Institute | 2005-03-01 |
| Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction (NCT00145041) | Acrotech Biopharma Inc. | 2005-02-01 |
| Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma (NCT00145145) | Ludwig Institute for Cancer Research | 2005-01-12 |
| Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma (NCT01247623) | Oslo University Hospital | 2005-01-01 |
| Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma (NCT00145158) | Ludwig Institute for Cancer Research | 2005-01-01 |
| Efficacy Study of IL-21 to Treat Metastatic Melanoma (NCT00336986) | Novo Nordisk A/S | 2004-09-01 |
| GM-CSF as Adjuvant Therapy of Melanoma (NCT00350597) | Northern California Melanoma Center | 2004-09-01 |
| Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients (NCT00204607) | University Hospital Tuebingen | 2004-07-01 |
| Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma (NCT00323206) | H. Lee Moffitt Cancer Center and Research Institute | 2004-06-01 |
| A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies (NCT02829775) | Hoffmann-La Roche | 2004-01-01 |
| A Pilot Study of Pivanex in Patients With Malignant Melanoma (NCT00087477) | Titan Pharmaceuticals | 2004-01-01 |
| CP-675,206 In Patients With Advanced Melanoma (NCT00086489) | AstraZeneca | 2003-08-01 |
| Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (NCT00729950) | Bristol-Myers Squibb | 2003-07-01 |
| Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer (NCT00108875) | Julius-Maximilians University | 2003-04-01 |
| Post-Operative Drainage Following Lymph Node Dissection (NCT00324272) | Oxford University Hospitals NHS Trust | 2003-01-01 |
| CP-461 in the Treatment of Patients With Advanced Melanoma (NCT00060710) | Astellas Pharma Inc | 2003-01-01 |
| A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma (NCT00203008) | Teva Branded Pharmaceutical Products R&D, Inc. | 2003-01-01 |
| Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma (NCT00087776) | American Regent, Inc. | 2002-12-06 |
| Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma (NCT00911443) | sigma-tau i.f.r. S.p.A. | 2002-07-01 |
| Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma (NCT01359956) | National Cancer Institute, Naples | 2002-04-01 |
| Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes (NCT00287196) | Trans Tasman Radiation Oncology Group | 2002-03-01 |
| Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma (NCT00039000) | Agenus Inc. | 2002-03-01 |
| Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma (NCT01278940) | Oslo University Hospital | 2002-03-01 |
| Phase II Trial of Allovectin-7® for Metastatic Melanoma (NCT00044356) | Vical | 2001-02-01 |
| Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]) (NCT00179764) | Ann & Robert H Lurie Children's Hospital of Chicago | 2000-03-10 |
| Optical Biopsy of Human Skin in Conjunction With Laser Treatment (NCT00540566) | University of California, Irvine | 1999-06-01 |
| Vaccine Therapy for Patients With Stage III Melanoma (NCT00052130) | CancerVax Corporation | |
| A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma (NCT00733798) | TransMolecular | |
| Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients (NCT00306553) | Cytos Biotechnology AG | |
| Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma (NCT00535314) | Biogen | |
| Vaccine Therapy for Patients With Stage IV Melanoma (NCT00052156) | CancerVax Corporation | |
| Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients (NCT00306566) | Cytos Biotechnology AG | |
| Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma (NCT02186249) | Bristol-Myers Squibb | |